Lipella Pharmaceuticals Common Stock Performance
| LIPO Stock | 2.18 0.05 2.24% |
The company secures a Beta (Market Risk) of 0.43, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Lipella Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Lipella Pharmaceuticals is expected to be smaller as well. At this point, Lipella Pharmaceuticals has a negative expected return of -0.7%. Please make sure to verify Lipella Pharmaceuticals' treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Lipella Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Lipella Pharmaceuticals Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in June 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return (2.24) | Five Day Return (8.40) | Year To Date Return (31.45) | Ten Year Return (62.09) | All Time Return (62.09) |
Last Split Factor 1:8 | Last Split Date 2024-11-08 |
1 | Lipella Pharmaceuticals Revises Placement Agent Agreement Terms | 02/26/2025 |
2 | Acquisition by Johnston Douglas of 50000 shares of Lipella Pharmaceuticals at 0.77 subject to Rule 16b-3 | 02/27/2025 |
3 | Acquisition by Kaufman Jonathan H of 125833 shares of Lipella Pharmaceuticals at 1.0 subject to Rule 16b-3 | 02/28/2025 |
4 | Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.s 3,788,000 Private Placement | 03/04/2025 |
5 | Acquisition by Kaufman Jonathan H of 28924 shares of Lipella Pharmaceuticals at 1.0 subject to Rule 16b-3 | 03/10/2025 |
6 | Acquisition by Kaufman Jonathan H of 4060 shares of Lipella Pharmaceuticals at 1.0 subject to Rule 16b-3 | 03/13/2025 |
7 | Disposition of 4060 shares by Kaufman Jonathan H of Lipella Pharmaceuticals at 1.0 subject to Rule 16b-3 | 04/03/2025 |
8 | Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus | 04/08/2025 |
9 | Acquisition by Chancellor Michael B of 144906 shares of Lipella Pharmaceuticals at 0.6901 subject to Rule 16b-3 | 04/09/2025 |
10 | Lipella Pharmaceuticals Shows Promising Phase 2a Results for Oral Lichen Planus ... | 04/22/2025 |
11 | Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment | 04/23/2025 |
12 | LIPO Lipella Pharmaceuticals Reports Promising Phase 2a Trial Results for LP-310 LIPO Stock News | 05/15/2025 |
| Begin Period Cash Flow | 3.3 M |
Lipella Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 360.00 in Lipella Pharmaceuticals Common on February 16, 2025 and sell it today you would lose (142.00) from holding Lipella Pharmaceuticals Common or give up 39.44% of portfolio value over 90 days. Lipella Pharmaceuticals Common is currently does not generate positive expected returns and assumes 4.1393% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than Lipella, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Lipella Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lipella Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Lipella Pharmaceuticals Common, and traders can use it to determine the average amount a Lipella Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.168
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | LIPO |
Estimated Market Risk
| 4.14 actual daily | 37 63% of assets are more volatile |
Expected Return
| -0.7 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.17 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Lipella Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lipella Pharmaceuticals by adding Lipella Pharmaceuticals to a well-diversified portfolio.
Lipella Pharmaceuticals Fundamentals Growth
Lipella Stock prices reflect investors' perceptions of the future prospects and financial health of Lipella Pharmaceuticals, and Lipella Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lipella Stock performance.
| Return On Equity | -1.55 | ||||
| Return On Asset | -0.81 | ||||
| Operating Margin | (10.26) % | ||||
| Current Valuation | 3.42 M | ||||
| Shares Outstanding | 2.55 M | ||||
| Price To Book | 2.89 X | ||||
| Price To Sales | 10.69 X | ||||
| Revenue | 536.36 K | ||||
| Gross Profit | (3.24 M) | ||||
| EBITDA | (5.01 M) | ||||
| Net Income | (5.02 M) | ||||
| Total Debt | 47.6 K | ||||
| Book Value Per Share | 1.60 X | ||||
| Cash Flow From Operations | (3.95 M) | ||||
| Earnings Per Share | (4.79) X | ||||
| Market Capitalization | 5.56 M | ||||
| Total Asset | 2.67 M | ||||
| Retained Earnings | (15.34 M) | ||||
| Working Capital | 1.86 M | ||||
About Lipella Pharmaceuticals Performance
By examining Lipella Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Lipella Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Lipella Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (14.65) | (15.39) | |
| Return On Tangible Assets | (1.88) | (1.78) | |
| Return On Capital Employed | (2.65) | (2.51) | |
| Return On Assets | (1.88) | (1.78) | |
| Return On Equity | (2.61) | (2.48) |
Things to note about Lipella Pharmaceuticals performance evaluation
Checking the ongoing alerts about Lipella Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Lipella Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Lipella Pharmaceuticals generated a negative expected return over the last 90 days | |
| Lipella Pharmaceuticals has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 536.36 K. Net Loss for the year was (5.02 M) with loss before overhead, payroll, taxes, and interest of (3.24 M). | |
| Lipella Pharmaceuticals generates negative cash flow from operations | |
| Latest headline from gurufocus.com: LIPO Lipella Pharmaceuticals Reports Promising Phase 2a Trial Results for LP-310 LIPO Stock News |
- Analyzing Lipella Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lipella Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Lipella Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lipella Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lipella Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Lipella Pharmaceuticals' stock. These opinions can provide insight into Lipella Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipella Pharmaceuticals Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipella Pharmaceuticals. If investors know Lipella will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipella Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.79) | Revenue Per Share | Quarterly Revenue Growth (0.11) | Return On Assets | Return On Equity |
The market value of Lipella Pharmaceuticals is measured differently than its book value, which is the value of Lipella that is recorded on the company's balance sheet. Investors also form their own opinion of Lipella Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Lipella Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipella Pharmaceuticals' market value can be influenced by many factors that don't directly affect Lipella Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipella Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipella Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipella Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.